Gastric Cancer Connect
  • Saved
RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes - PubMed

RNA-binding protein ENO1 promotes the tumor progression of gastric cancer by binding to and regulating gastric cancer-related genes - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37201055/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusions: ENO1 may play a role in GC by binding to and regulating GC-related genes. Our findings extend understandings of its mechanism as a clinical therapeutic target.

  • Saved
Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer - Surgical Case Reports

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer - Surgical Case Reports

Source : https://surgicalcasereports.springeropen.com/articles/10.1186/s40792-023-01668-x

Background Advanced gastric cancer has an unfavorable prognosis and poor curability. Immune checkpoint inhibitors, such as nivolumab, have recently emerged as a potential solution for this aggressive disease. However, there...

Conclusion: Here, we report a case of recurrent gastric cancer with liver metastasis, where complete pathological response was achieved with nivolumab. PET–CT could aid in making treatment strategy decisions about the need for surgical intervention.
 

  • Saved
The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review - PubMed

The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37176668/

Since bevacizumab was first approved by the U.S. Food and Drug Administration as an anti-angiogenic therapy in 2004, angiogenesis-targeted therapy has been developed for various types of solid tumors. To...

Relevance: This review offers an overview of the history of clinical trials focused on anti-angiogenic for patients with AGC and presents future perspectives in this area.

  • Saved
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis - PubMed

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/30470690/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusion: We provide the first data suggesting FOLFIRI-ram is a safe, non-neurotoxic regimen comparing favorably with the combination of pac + ram used in the seminal RAINBOW trial.

  • Saved
Transcriptomic dataset reveals the molecular basis of genotypic variation in hexaploid wheat ( T. aestivum L.) in response to Fe/Zn deficiency - PubMed

Transcriptomic dataset reveals the molecular basis of genotypic variation in hexaploid wheat ( T. aestivum L.) in response to Fe/Zn deficiency - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/32685638/

The datasets depicted in the paper are related to the original article entitled "Identifying transcripts associated with efficient transport and accumulation of Fe and Zn in hexaploid wheat ( T....

Conclusions/Relevance: In real-world routine practice in the US during April 2014 through June 2020, patients with advanced gastric, esophageal, or GEJ cancer who received both RAM and ICI typically received RAM before an ICI, with RAM most commonly administered in 2L therapy. Among the different RAM-containing regimens, RAM + PAC was the...